ZyVersa Therapeutics, Inc.

NasdaqCM ZVSA

ZyVersa Therapeutics, Inc. Net Income Margin for the Trailing 12 Months (TTM) ending September 30, 2024: -15,514,006.28%

ZyVersa Therapeutics, Inc. Net Income Margin is -15,514,006.28% for the Trailing 12 Months (TTM) ending September 30, 2024. Net Income Ratio, also known as the profit margin, is the ratio of net income to net sales, showing the percentage of revenue that remains as profit after all expenses are deducted.

Key data

Date	Net Income Margin	EBITDA Margin	EBIT Margin	EBITDA

NasdaqCM: ZVSA

ZyVersa Therapeutics, Inc.

CEO	Mr. Stephen C. Glover
IPO Date	Feb. 11, 2022
Location	United States
Headquarters	2200 N. Commerce Parkway
Employees	7
Sector	Health Care
Industries Pharmaceuticals Biotechnology Clinical Trials

Description

ZyVersa Therapeutics, Inc., a clinical stage biopharmaceutical company, develops and commercializes products for the treatment of renal and inflammatory diseases. It engages in the development of VAR 200, a cholesterol efflux mediator to treat focal segmental glomerulosclerosis, alport syndrome, and diabetic kidney disease; and IC 100, a novel inflammasome ASC inhibitor for treatment of multitude of inflammatory diseases. ZyVersa Therapeutics, Inc. is headquartered in Weston, Florida.

Key trends

Past 5 years